Roche Plans Major Biologics Manufacturing Investment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Roche Plans Major Biologics Manufacturing Investment


Roche plans to invest CHF 800 million ($879 million) within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. The investment will be spread across sites in the following locations: Penzberg, Germany; Basel, Switzerland; and Vacaville and Oceanside, California in the United States. Approximately 500 new jobs are expected to be created in conjunction with the facility expansions.

The investment will support increasing demand for Roche's licensed biologic medicines, such as RoACTEMRA (tocilizumab), Kadcyla (trastuzumab emtansine), and Perjeta (pertuzumab) as well as provide a manufacturing foundation for 39 investigational biologic medicines in the Roche pipeline.

Biologic manufacturing capacity will be increased at sites in Vacaville and Oceanside with a planned investment of approximately CHF 260 million ($285.6 million) and create approximately 250 new jobs. In Penzberg, Roche will invest approximately CHF 350 million ($384 million) toward increased manufacturing capacity and equipment refurbishment and create approximately 200 positions.

In addition, Roche will construct an antibody-drug conjugate (ADC) production facility in Basel, Switzerland through an investment of more than CHF 190 million ($209 million), which is expected to create 50 jobs. This investment will provide additional capacity and flexibility to support Roche’s first approved ADC, Kadcyla, and a further eight ADCs in clinical development, according to Roche.

Source: Roche

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here